Distribution of total net revenues

SEK million

2018      

Apr-Jun

2017

Apr-Jun

2018      

Jan-Jun

2017      

Jan-Jun

12 mth    

Jul 2017- Jun 2018

12 mth    

Jul 2016- Jun 2017

Zubsolv® US

158.4

124.1

289.5

238.2

537.1

508.8

Zubsolv – Rest of the World

30.8

30.8

36.4

0.5

Zubsolv – total

189.2

124.1

320.3

238.2

573.5

509.3

Abstral® royalties

11.9

9.8

17.7

18.4

112.5

105.2

Milestone payment Abstral

2.2

Abstral – total

11.9

9.8

17.7

18.4

112.5

107.4

Edluar® royalties

-1.4

3.4

1.4

8.0

10.7

14.7

OX-CLI

21.8

21.8

21.8

Total

199.7

159.1

339.4

286.4

696.7

653.2

 

Key figures

 

2018    

Apr- Jun

2017    

Apr-Jun

2018

Jan-Jun

2017

Jan-Jun

2017

Jan-Dec

EBIT margin, %

22.7

6.2

6.9

-4.7

8.9

Return on shareholder equity, %

15.0

1.1

7.0

-10.8

7.3

Net debt, SEK million

-175.0

45.7

-175.0

45.7

-8.8

Debt/equity ratio, %

88.5

123.3

88.5

123.3

97.0

Equity/assets ratio, %

30.8

28.3

30.8

28.3

32.8

Number of shares, before dilution

34,581,327

34,539,585

34,581,327

34,539,585

34,561,142

Number of shares, after dilution

34,640,132

34,551,912

34,640,132

34,539,585

34,671,706

Earnings per share, before dilution, SEK

1.45

0.09

0.70

-0.91

0.67

Earnings per share, after dilution, SEK

1.45

0.09

0.70

-0.91

0.67

Number of employees at the end of the period

89

98

89

98

90

Shareholders’ equity, SEK million

361.3

275.8

361.3

275.8

329.1

Capital employed, SEK million

681.1

615.8

681.1

615.8

648.2

Working capital, SEK million

14.5

150.9

14.5

150.9

149.6

 

Cash flow

Cash flow

MSEK

Q2

2018

Q2

2017

H1

2018

H1

2017

LTM

July 2017-June 2018

Cash flow from operating activities

39.0

49.0

144.9

76.9

146.6

Investment activities

-1.7

-0.5

-1.7

-0.8

-1.6

Financing activities

0.5

-

0.9

-59.0

-85.4

Cash flow (excl exchange rate differences)

37.8

48.5

144.1

17.2

59.6

Liquid funds

498.4

294.3

494.8

294.3

327.9